SRR934946
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.688
- INTERFERON_GAMMA_RESPONSE+0.589
- TGF_BETA_SIGNALING+0.471
- ALLOGRAFT_REJECTION+0.450
- IL6_JAK_STAT3_SIGNALING+0.407
- MITOTIC_SPINDLE+0.338
- WNT_BETA_CATENIN_SIGNALING+0.327
- MYC_TARGETS_V1+0.326
- NOTCH_SIGNALING+0.321
- UNFOLDED_PROTEIN_RESPONSE+0.318
Top 10 suppressed
- KRAS_SIGNALING_DN-0.323
- SPERMATOGENESIS-0.300
- PANCREAS_BETA_CELLS-0.231
- MYOGENESIS-0.077
- OXIDATIVE_PHOSPHORYLATION-0.026
- ANGIOGENESIS+0.005
- APICAL_SURFACE+0.017
- HYPOXIA+0.021
- BILE_ACID_METABOLISM+0.028
- COAGULATION+0.028
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AD62B8A4-6AB8-4C99-80F5-98A1C085027D | — | — | 0.942 |
| 2 | 6292335B-7CBB-45BE-AA2A-B39FFDA8768D | — | — | 0.942 |
| 3 | B4E10042-052D-4DC4-BC94-FF1D5D4632C0 | — | — | 0.936 |
| 4 | SRR934949 | — | — | 0.927 |
| 5 | 9ECB653A-A04F-457C-92FC-D13424511A47 | — | — | 0.926 |
| 6 | 928D2F99-A86B-47CA-A961-A8CAE7B44E78 | — | — | 0.926 |
| 7 | B7B8F0C1-3C67-4582-AF82-A3DCD0398DEC | — | — | 0.923 |
| 8 | A9B59C46-7F32-4DD1-9649-B1788CA5E909 | — | — | 0.918 |
| 9 | 896B5096-D888-4DC3-9C70-152BDE083E26 | — | — | 0.918 |
| 10 | B583566B-A014-417A-A973-41204DC35ECF | — | — | 0.916 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.688 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.589 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.471 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.407 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.338 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.327 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.326 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.321 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.318 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.309 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.301 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.296 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.274 | Idelalisib | — uncovered |
| APOPTOSIS | 0.268 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.260 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.252 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.252 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.246 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |